Roivant Sciences (NASDAQ:ROIV) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research note released on Tuesday,Benzinga reports. They currently have a $18.00 price target on the stock.

Separately, Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $17.93.

Roivant Sciences Stock Down 2.8 %

Shares of NASDAQ:ROIV opened at $10.49 on Tuesday. The company has a market cap of $7.64 billion, a P/E ratio of 1.86 and a beta of 1.25. The business has a fifty day simple moving average of $11.48 and a 200-day simple moving average of $11.60. Roivant Sciences has a 52 week low of $9.76 and a 52 week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%. Sell-side analysts expect that Roivant Sciences will post -1.19 earnings per share for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00. Following the transaction, the chief operating officer now owns 606,525 shares of the company’s stock, valued at approximately $6,865,863. This trade represents a 14.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were acquired at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the transaction, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 1,942,629 shares of company stock valued at $23,034,486 over the last ninety days. Corporate insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds have recently modified their holdings of the stock. EntryPoint Capital LLC boosted its holdings in Roivant Sciences by 328.3% in the 4th quarter. EntryPoint Capital LLC now owns 53,443 shares of the company’s stock worth $632,000 after acquiring an additional 40,964 shares during the period. United Services Automobile Association lifted its position in shares of Roivant Sciences by 6.1% during the fourth quarter. United Services Automobile Association now owns 27,494 shares of the company’s stock worth $325,000 after purchasing an additional 1,588 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after purchasing an additional 2,404,232 shares during the period. LPL Financial LLC grew its holdings in Roivant Sciences by 11.3% during the 4th quarter. LPL Financial LLC now owns 73,308 shares of the company’s stock valued at $867,000 after purchasing an additional 7,452 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in Roivant Sciences during the 4th quarter worth $918,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.